FAQ Library

Join Paul Richardson, MD, in this Managing Myeloma FAQ as he describes how to address medication compliance and adherence in the outpatient setting to oral medicines that we use in myeloma.

Join Paul Richardson, MD, in this Managing Myeloma FAQ as he briefly discusses the Revised International Staging System (R-ISS).

Join Robert Orlowski, MD, PhD in this brief Managing Myeloma FAQ as he discusses why a myeloma patient who has previous history of bone lesions should have a bone study as part of their CR assessment.

Join Dr. Sagar Lonial in this brief discussion regarding the emerging therapy classes for multiple myeloma.

Join Dr. Jatin Shah as he explains when panobinostat should be used.

Join Dr. Jatin Shah as he explains whether or not the amount of time one has to achieve treatment goals in the patient governs choice.

Join Dr. Jatin Shah as he explains how the new diagnostic criteria will impact when to initiate therapy.

Join Dr. Jatin Shah as he describes how patients with smoldering multiple myeloma will be impacted by the new diagnostic criteria.

Join Dr. Philip McCarthy as he discusses the new Revised International Staging System for multiple myeloma and why it's critical that clinicians use it.

Join Dr. Usmani as he discusses the role of gene expression profiling in multiple myeloma and how it plays a positive role in myeloma treatment.